电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Regulatory Factor X 5 (RFX5) Peptide

RFX5 适用: 人 宿主: 合成 BP, WB
产品编号 ABIN982894
发货至: 中国
  • 抗原 See all RFX5 products
    RFX5 (Regulatory Factor X 5 (RFX5))
    宿主
    资源
    • 4
    合成
    应用范围
    Blocking Peptide (BP), Western Blotting (WB)
    产品特性
    This is a synthetic peptide designed for use in combination with anti-RFX5 antibody (Catalog #: ARP37992_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    纯化方法
    Purified
  • 应用备注
    Each Investigator should determine their own optimal working dilution for specific applications.
    限制
    仅限研究用
  • 状态
    Lyophilized
    溶解方式
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    浓度
    1 mg/mL
    缓冲液
    Final peptide concentration is 1 mg/mL in PBS.
    注意事项
    Avoid repeated freeze-thaw cycles.
    储存条件
    -20 °C
    储存方法
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • 抗原
    RFX5 (Regulatory Factor X 5 (RFX5))
    背景
    RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. RFX is a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.

    Protein Interaction Partner: CIITA,HDAC2,RFXANK,RFXAP,CIITA,RFXANK,RFXAP

    Protein Size: 616
    分子量
    68 kDa
    基因ID
    5993
    NCBI登录号
    NM_001025603, NP_001020774
    UniProt
    P48382
You are here:
客服